Business Context and Reporting Period
Company: Absci Corp (ABSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Absci is a clinical-stage biopharmaceutical company utilizing an AI-native "Integrated Drug Creation" platform to develop antibody-based therapeutics. The company focuses on internally developed programs (e.g., ABS-201 for androgenetic alopecia and endometriosis) and partnered drug creation agreements.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Partner Program Revenue | $215 | $1,179 |
| Total Operating Expenses | $31,061 | $28,908 |
| Net Loss | $(29,599) | $(26,346) |
| Net Loss Per Share (Basic & Diluted) | $(0.19) | $(0.21) |
| Cash, Cash Equivalents & Marketable Securities | $125,705 | $144,292 |
| Accumulated Deficit | $(654,383) | $(535,947) |
| Long-term Debt | $413 | $873 |
Note: Cash, cash equivalents, and marketable securities are derived from the Balance Sheet (Cash: $8,627; Marketable Securities: $117,078; Restricted Cash: $1,062).
Material Changes vs. Prior Period
- Revenue Decline: Partner program revenue decreased by $0.96 million (82%) to $0.2 million. This was driven by the timing of project-based milestones and the mix of ongoing program activity. Two partners represented 100% of revenue in Q1 2026.
- Expense Increase: Total operating expenses increased by $2.2 million (7%) to $31.1 million.
- R&D Expenses: Increased by $2.9 million (18%) to $19.3 million, primarily due to a $1.6 million increase in external preclinical/clinical development costs for ABS-201 and a $2.1 million increase in drug creation/platform costs.
- SG&A Expenses: Decreased by $0.4 million (4%) to $9.1 million, largely due to lower personnel and stock-based compensation costs.
- Net Loss Expansion: Net loss increased by $3.3 million (12%) to $29.6 million, reflecting the revenue decline and increased R&D spend.
- Liquidity Position: Cash and marketable securities decreased by approximately $18.6 million quarter-over-quarter, primarily due to operating cash outflows of $26.3 million, partially offset by financing proceeds.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Capital Runway: Management believes current cash, cash equivalents, and marketable securities ($125.7 million) are sufficient to meet operating needs for at least the next 12 months.
- Pipeline Progress:
- ABS-201 (AGA): The HEADLINE Phase 1/2a trial has dosed all four single ascending dose (SAD) cohorts with a favorable safety profile. Dosing of the first multiple ascending dose (MAD) cohort has begun. Two additional MAD cohorts are expected to initiate in Q2 2026. Interim proof-of-concept data is expected in H2 2026.
- ABS-201 (Endometriosis): A Phase 2 trial is anticipated to initiate in Q4 2026, subject to data review.
- Financing Activity: During Q1 2026, the company raised $8.0 million in net proceeds through its "at-the-market" (ATM) offering program.
Risks and Contingencies
- Capital Needs: The company expects to incur significant losses in the future and will need to raise additional capital to fund operations and development. Failure to secure funding could harm operations.
- Development Uncertainty: Biologic drug development is inherently uncertain. Early positive results (e.g., in preclinical or Phase 1 trials) are not predictive of later-stage success.
- Revenue Concentration: Revenue is highly concentrated; two partners accounted for 100% of revenue in Q1 2026. Future revenue depends on partners achieving milestones and entering into long-term license agreements.
- Regulatory & AI Risks: The company faces risks related to FDA regulatory reviews, potential government shutdowns, and evolving regulations regarding the use of AI in drug discovery (e.g., EU AI Act).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $26.3 million quarterly operating cash burn against the $125.7 million liquidity position.
- Revenue Visibility: Assess the likelihood of future milestone payments given the 82% revenue drop and reliance on just two partners.
- ABS-201 Trial Data: Monitor the upcoming interim proof-of-concept data for the AGA indication (expected H2 2026) as a key value driver.
- ATM Offering Usage: Track the utilization of the remaining capacity under the $100 million ATM agreement and the impact of share issuance on dilution.
- Partnership Conversions: Evaluate progress in converting drug creation agreements into long-term license agreements with royalty and milestone obligations.